Established in 1941, a pharmaceutical company is headquartered in Tokyo, Japan, operating globally in terms of R&D, manufacturing, distribution and marketing, with a strong focus on prescription medicines. The corporate investment arm of the company has offices in USA and a headquarter in Tokyo, Japan. The firm has a budget of $140M USD ($15B JPY) to make strategic equity investments in early-stage companies that align with the company’s core business. The firm will invest between $1-5M in seed to mid-stage companies, with Series A being the sweet spot. The firm is open to global opportunities.
The firm is interested in opportunities that are synergistic with their research and development pipeline in neurology and oncology. The firm is interested in pharmaceutical drugs across various modalities, including but not limited to antibodies, peptides, nucleic acids, and cell/gene therapy. The firm is also interested in digital therapeutics, IT solutions, and diagnostics. Within neurology, the firm is strongly interested in (but not limited to) neurodegenerative diseases including Alzheimer’s Disease and Parkinson’s Disease as well as epilepsy and sleep disorders. Within oncology, the firm is interested in solid tumors (breast, liver, lung, etc).
The firm is a flexible investor and can act as a lead or follow-on investor. The corporate venture investment closely collaborates with the firm’s business development and leverages its global network of pharmaceuticals, research universities, etc. to identify and collaborate with cutting-edge opportunities.
If you are interested in more information about this investor and other investors tracked by LSN, please email resi@lifesciencenation.com.
Next Phase Newsletter 
Leave a Reply